Advanced Seminoma and Nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009 (Q30318289)

17 June 2017

title

Advanced Seminoma and Nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009 (English)

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

14 December 2024

5

Karim Fizazi

1 reference

17 June 2017

Hans-Joachim Schmoll

1

1 reference

17 June 2017

Susanne Osanto

series ordinal

2

1 reference

17 June 2017

Koji Kawai

series ordinal

3

1 reference

17 June 2017

Lawrence Einhorn

series ordinal

4

1 reference

17 June 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

17 June 2017

October 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21986225

full work available at URL

14 December 2024

https://api.elsevier.com/content/article/PII:S0090429511021856?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

https://api.elsevier.com/content/article/PII:S0090429511021856?httpAccept=text/plain

14 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

14 December 2024

1 reference

17 June 2017

volume

78

1 reference

17 June 2017

issue

4 Suppl

1 reference

17 June 2017

page(s)

S456-68

1 reference

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

17 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Ca

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Resear

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Ca

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

A randomized trial of etoposide cisplatin versus vinblastine bleomycin cisplatin cyclophosphamide dactinomycin in patients with good-prognosis germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2011.08.001

7 January 2021

Identifiers

1 reference

17 June 2017

1 reference